Please login to the form below

Not currently logged in
Email:
Password:

AstraZeneca posts disappointing Q1 figures

AstraZeneca reveals fall in first-quarter sales and profit following increased generic competition and government price intervention

AstraZeneca has reported a 6 per cent fall in pre-tax profit to $3.3bn, at constant exchange rates (CER), for the first quarter of 2011.

Revenue for the period was $8.3bn, down 4 per cent, reflecting the loss of more than $550m of revenue from generic competition, as well as the impact from government price interventions. However, the company said revenue from emerging markets increased by 13 per cent at CER.

David Brennan, chief executive, said: "Our first quarter revenue performance reflects the anticipated generic competition in the US and Western Europe, which we partially mitigated by our continued double digit growth in emerging markets. We remain focused on driving operating performance in order to invest in the development of innovative new products while providing attractive cash returns to shareholders."

The company reported that it spent $143m on restructuring costs in the first quarter, related to previously announced business reshaping programmes. It said that the programmes remain on track for costs incurred and benefits achieved.

The company said it continues to anticipate that revenue for the full year could range from flat to a low-single digit decline compared with 2010 on a constant currency basis.

28th April 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
AMICULUM Limited

AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >220 healthcare communications professionals,...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics